PanCareSurPass Project HL7 FHIR Implementation Guide
1.0.0 - release 150

PanCareSurPass Project HL7 FHIR Implementation Guide, published by PanCareSurPass Project. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/pcsp/ and changes regularly. See the Directory of published versions

ValueSet: Antineoplastic and immunostimulating agents

Official URL: http://hl7.eu/fhir/ig/pcsp/ValueSet/drugsAtc-eu-pcsp Version: 1.0.0
Active as of 2025-10-16 Computable Name: VsPcspAtcCodes

List of WHO ATC codes for antineoplastic and immunostimulating agents.

References

Logical Definition (CLD)

  • Include these codes as defined in http://www.whocc.no/atc version Not Stated (use latest from terminology server)
    CodeDisplay
    L01AA01Cyclophosphamide
    L01AA02Chlorambucil
    L01AA03Melphalan
    L01AA05Chlormethine
    L01AA06Ifosfamide
    L01AA07Trofosfamide
    L01AA08Prednimustine
    L01AA09Bendamustine
    L01AB01Busulfan
    L01AB02Treosulfan
    L01AB03Mannosulfan
    L01AC01Thiotepa
    L01AC02Triaziquone
    L01AC03Carboquone
    L01AD01Carmustine
    L01AD02Lomustine
    L01AD03Semustine
    L01AD04Streptozocin
    L01AD05Fotemustine
    L01AD06Nimustine
    L01AD07Ranimustine
    L01AG01Etoglucid
    L01AXPeptichemio
    L01AX01Mitobronitol
    L01AX02Pipobroman
    L01AX03Temozolomide
    L01AX04Dacarbazine
    L01BA01Methotrexate
    L01BA03Raltitrexed
    L01BA04Pemetrexed
    L01BA05Pralatrexate
    L01BB02Mercaptopurine
    L01BB03Thioguanine
    L01BB04Cladribine
    L01BB05Fludarabine
    L01BB06Clofarabine
    L01BB07Nelarabine
    L01BC01Cytarabine
    L01BC02Fluorouracil
    L01BC03Tegafur
    L01BC04Carmofur
    L01BC05Gemcitabine
    L01BC06Capecitabine
    L01BC07Azacitidine
    L01BC08Decitabine
    L01BC52Fluorouracil, combinations
    L01BC53Tegafur, combinations
    L01BC59Trifluridine, combinations
    L01CA01Vinblastine
    L01CA02Vincristine
    L01CA03Vindesine
    L01CA04Vinorelbine
    L01CA05Vinflunine
    L01CA06Vintafolide
    L01CB01Etoposide
    L01CB02Teniposide
    L01CC01Demecolcine
    L01CD01Paclitaxel
    L01CD02Docetaxel
    L01CD03Paclitaxel poliglumex
    L01CD04Cabazitaxel
    L01CX01Trabectedin
    L01DA01Dactinomycin
    L01DB01Doxorubicin
    L01DB02Daunorubicin
    L01DB03Epirubicin
    L01DB04Aclarubicin
    L01DB05Zorubicin
    L01DB06Idarubicin
    L01DB07Mitoxantrone
    L01DB08Pirarubicin
    L01DB09Valrubicin
    L01DB10Amrubicin
    L01DB11Pixantrone
    L01DC01Bleomycin
    L01DC02Mithramycin
    L01DC03Mitomycin
    L01DC04Ixabepilone
    L01XA01Cisplatin
    L01XA02Carboplatin
    L01XA03Oxaliplatin
    L01XA04Satraplatin
    L01XA05Polyplatillen
    L01XB01Procarbazine
    L01FX01Edrecolomab
    L01FA01Rituximab
    L01FD01Trastuzumab
    L04AG06Alemtuzumab
    L01FX02Gemtuzumab
    L01FE01Cetuximab
    L01FG01Bevacizumab
    L01FE02Panitumumab
    L01FX03Catumaxomab
    L01FA02Ofatumumab
    L01FX04Ipilimumab
    L01FX05Brentuximab vedotin
    L01FD02Pertuzumab
    L01FD03Trastuzumab emtansine
    L01FA03Obinutuzumab
    L01FX06Dinutuximab
    L01FF01Nivolumab
    L01FF02Pembrolizumab
    L01FX07Blinatumomab
    L01FG02Ramucirumab
    L01FE03Necitumumab
    L01FX08Elotuzumab
    L01FC01Daratumumab
    L01FX09Mogamulizumab
    L01FB01Inotuzumab ozogamicin
    L01FX10Olaratumab
    L01XD01Porfimer sodium
    L01XD03Methyl aminolevulinate
    L01XD04Aminolevulinic acid
    L01XD05Temoporfin
    L01XD06Efaproxiral
    L01EA01Imatinib
    L01EB01Gefitinib
    L01EB02Erlotinib
    L01EX01Sunitinib
    L01EX02Sorafenib
    L01EA02Dasatinib
    L01EH01Lapatinib
    L01EA03Nilotinib
    L01EG01Temsirolimus
    L01EG02Everolimus
    L01EX03Pazopanib
    L01EX04Vandetanib
    L01EB03Afatinib
    L01EA04Bosutinib
    L01EC01Vemurafenib
    L01ED01Crizotinib
    L01EK01Axitinib
    D11AH09Ruxolitinib
    L01EG03Ridaforolimus
    L01EX05Regorafenib
    L01EX06Masitinib
    L01EC02Dabrafenib
    L01EA05Ponatinib
    L01EE01Trametinib
    L01EX07Cabozantinib
    L01EL01Ibrutinib
    L01ED02Ceritinib
    L01EX08Lenvatinib
    L01EX09Nintedanib
    L01EK02Cediranib
    L01EF01Palbociclib
    L01EK03Tivozanib
    L01EB04Osimertinib
    L01ED03Alectinib
    L01EB05Rociletinib
    L01EE02Cobimetinib
    L01EX10Midostaurin
    L01EB06Olmutinib
    L01XXOther antineoplastic agent
    L01XX01Amsacrine
    L01XX02Asparaginase
    L01XX03Altretamine
    L01XX05Hydroxycarbamide
    L01XX07Lonidamine
    L01XX08Pentostatin
    P01CX04Miltefosine
    L01XX10Masoprocol
    L01XX11Estramustine
    D10AD01Tretinoin
    L01XX16Mitoguazone
    L01CE01Topotecan
    L01XX18Tiazofurine
    L01CE02Irinotecan
    D11AH04Alitretinoin
    L01XX23Mitotane
    L01XX24Pegaspargase
    L01XF03Bexarotene
    L01XX27Arsenic trioxide
    L01XX29Denileukin diftitox
    L01XG01Bortezomib
    L01XX33Celecoxib
    L01XX35Anagrelide
    L01XX36Oblimersen
    L01XL01Sitimagene ceradenovec
    L01XH01Vorinostat
    L01XH02Romidepsin
    L01XX40Omacetaxine mepesuccinate
    L01XX41Eribulin
    L01XH03Panobinostat
    L01XJ01Vismodegib
    L01XX44Aflibercept
    L01XG02Carfilzomib
    L01XK01Olaparib
    L01EM01Idelalisib
    L01XJ02Sonidegib
    L01XH04Belinostat
    L01XG03Ixazomib
    L01XL02Talimogene laherparepvec
    L01XX52Venetoclax
    L01XX53Vosaroxin
    L01XYCombination of antineoplastic agents
    G03CB02Diethylstilbestrol
    L02AA02Polyestradiol phosphate
    G03CA01Ethinylestradiol
    L02AA04Fosfestrol
    G03AC05Megestrol
    G03AC06Medroxyprogesterone
    G03DA01Gestonorone
    L02AE01Buserelin
    L02AE02Leuprorelin
    L02AE03Goserelin
    L02AE04Triptorelin
    L02AE05Histrelin
    L02BA01Tamoxifen
    L02BA02Toremifene
    L02BA03Fulvestrant
    L02BB01Flutamide
    L02BB02Nilutamide
    L02BB03Bicalutamide
    L02BB04Enzalutamide
    L02BG01Aminogluthetimide
    L02BG02Formestane
    L02BG03Anastrozole
    L02BG04Letrozole
    L02BG05Vorozole
    L02BG06Exemestane
    L02BX01Abarelix
    L02BX02Degarelix
    L02BX03Abiraterone
    L03AA02Filgrastim
    L03AA03Molgramostim
    L03AA09Sargramostim
    L03AA10Lenograstim
    L03AA12Ancestim
    L03AA13Pegfilgrastim
    L03AA14Lipegfilgrastim
    L03AA15Balugrastim
    L03AA16Empegfilgrastim
    L03AB01Interferon alfa natural
    L03AB02Interferon beta natural
    L03AB03Interferon gamma
    L03AB04Interferon alfa-2a
    L03AB05Interferon alfa-2b
    L03AB06Interferon alfa-n1
    L03AB07Interferon beta-1a
    L03AB08Interferon beta-1b
    L03AB09Interferon alfacon-1
    L03AB10Peginterferon alfa-2b
    L03AB11Peginterferon alfa-2a
    L03AB12Albinterferon alfa-2b
    L03AB13Peginterferon beta-1a
    L03AB14Cepeginterferon alfa-2b
    L03AB60Peginterferon alfa-2b, combinations
    L03AB61Peginterferon alfa-2a, combinations
    L03AC01Aldesleukin
    L03AC02Oprelvekin
    L03AX01Lentinan
    L03AX02Roquinimex
    L03AX03BCG vaccine
    L03AX04Pegademase
    L03AX05Pidotimod
    L03AX07Poly I:C
    L03AX08Poly ICLC
    L03AX09Thymopentin
    L03AX10Immunocyanin
    L03AX11Tasonermin
    L03AX12Melanoma vaccine
    L03AX13Glatiramer acetate
    L03AX14Histamine dihydrochloride
    L03AX15Mifamurtide
    L03AX16Plerixafor
    L03AX17Sipuleucel-T
    L03AX18Cridanimod
    L03AX19Dasiprotimut-T
    L04AG01Muromonab-CD3
    L04AA03Antilymphocyte immunoglobulin (horse)
    L04AA04Antithymocyte immunoglobulin (rabbit)
    L04AA06Mycophenolic acid
    L01EG04Sirolimus
    L04AK01Leflunomide
    L04AA15Alefacept
    L04AA19Gusperimus
    L04AG02Efalizumab
    L04AA22Abetimus
    L04AG03Natalizumab
    L04AA24Abatacept
    L04AJ01Eculizumab
    L04AG04Belimumab
    L04AE01Fingolimod
    L04AA28Belatacept
    L04AF01Tofacitinib
    L04AK02Teriflunomide
    L04AA32Apremilast
    L04AG05Vedolizumab
    L04AG07Begelomab
    L04AG08Ocrelizumab
    L04AF02Baricitinib
    L04AB01Etanercept
    L04AB02Infliximab
    L04AB03Afelimomab
    L04AB04Adalimumab
    L04AB05Certolizumab pegol
    L04AB06Golimumab
    L04AC01Daclizumab
    L04AC02Basiliximab
    L04AC03Anakinra
    L04AC04Rilonacept
    L04AC05Ustekinumab
    R03DX09Mepolizumab
    L04AC07Tocilizumab
    L04AC08Canakinumab
    L04AC09Briakinumab
    L04AC10Secukinumab
    L04AC11Siltuximab
    L04AC12Brodalumab
    L04AC13Ixekizumab
    L04AC14Sarilumab
    L04AD01Ciclosporin
    D11AH01Tacrolimus
    L04AD03Voclosporin
    L04AX01Azathioprine
    L04AX02Thalidomide
    L04AX04Lenalidomide
    L04AX05Pirfenidone
    L04AX06Pomalidomide

 

Expansion

Expansion from tx.fhir.org based on codesystem WHO ATC version 2025

This value set contains 320 concepts

SystemCodeDisplay (en)JSONXML
http://www.whocc.no/atc  L01AA01cyclophosphamide
http://www.whocc.no/atc  L01AA02chlorambucil
http://www.whocc.no/atc  L01AA03melphalan
http://www.whocc.no/atc  L01AA05chlormethine
http://www.whocc.no/atc  L01AA06ifosfamide
http://www.whocc.no/atc  L01AA07trofosfamide
http://www.whocc.no/atc  L01AA08prednimustine
http://www.whocc.no/atc  L01AA09bendamustine
http://www.whocc.no/atc  L01AB01busulfan
http://www.whocc.no/atc  L01AB02treosulfan
http://www.whocc.no/atc  L01AB03mannosulfan
http://www.whocc.no/atc  L01AC01thiotepa
http://www.whocc.no/atc  L01AC02triaziquone
http://www.whocc.no/atc  L01AC03carboquone
http://www.whocc.no/atc  L01AD01carmustine
http://www.whocc.no/atc  L01AD02lomustine
http://www.whocc.no/atc  L01AD03semustine
http://www.whocc.no/atc  L01AD04streptozocin
http://www.whocc.no/atc  L01AD05fotemustine
http://www.whocc.no/atc  L01AD06nimustine
http://www.whocc.no/atc  L01AD07ranimustine
http://www.whocc.no/atc  L01AG01etoglucid
http://www.whocc.no/atc  L01AXOther alkylating agents
http://www.whocc.no/atc  L01AX01mitobronitol
http://www.whocc.no/atc  L01AX02pipobroman
http://www.whocc.no/atc  L01AX03temozolomide
http://www.whocc.no/atc  L01AX04dacarbazine
http://www.whocc.no/atc  L01BA01methotrexate
http://www.whocc.no/atc  L01BA03raltitrexed
http://www.whocc.no/atc  L01BA04pemetrexed
http://www.whocc.no/atc  L01BA05pralatrexate
http://www.whocc.no/atc  L01BB02mercaptopurine
http://www.whocc.no/atc  L01BB03tioguanine
http://www.whocc.no/atc  L01BB04cladribine
http://www.whocc.no/atc  L01BB05fludarabine
http://www.whocc.no/atc  L01BB06clofarabine
http://www.whocc.no/atc  L01BB07nelarabine
http://www.whocc.no/atc  L01BC01cytarabine
http://www.whocc.no/atc  L01BC02fluorouracil
http://www.whocc.no/atc  L01BC03tegafur
http://www.whocc.no/atc  L01BC04carmofur
http://www.whocc.no/atc  L01BC05gemcitabine
http://www.whocc.no/atc  L01BC06capecitabine
http://www.whocc.no/atc  L01BC07azacitidine
http://www.whocc.no/atc  L01BC08decitabine
http://www.whocc.no/atc  L01BC52fluorouracil, combinations
http://www.whocc.no/atc  L01BC53tegafur, combinations
http://www.whocc.no/atc  L01BC59trifluridine, combinations
http://www.whocc.no/atc  L01CA01vinblastine
http://www.whocc.no/atc  L01CA02vincristine
http://www.whocc.no/atc  L01CA03vindesine
http://www.whocc.no/atc  L01CA04vinorelbine
http://www.whocc.no/atc  L01CA05vinflunine
http://www.whocc.no/atc  L01CA06vintafolide
http://www.whocc.no/atc  L01CB01etoposide
http://www.whocc.no/atc  L01CB02teniposide
http://www.whocc.no/atc  L01CC01demecolcine
http://www.whocc.no/atc  L01CD01paclitaxel
http://www.whocc.no/atc  L01CD02docetaxel
http://www.whocc.no/atc  L01CD03paclitaxel poliglumex
http://www.whocc.no/atc  L01CD04cabazitaxel
http://www.whocc.no/atc  L01CX01trabectedin
http://www.whocc.no/atc  L01DA01dactinomycin
http://www.whocc.no/atc  L01DB01doxorubicin
http://www.whocc.no/atc  L01DB02daunorubicin
http://www.whocc.no/atc  L01DB03epirubicin
http://www.whocc.no/atc  L01DB04aclarubicin
http://www.whocc.no/atc  L01DB05zorubicin
http://www.whocc.no/atc  L01DB06idarubicin
http://www.whocc.no/atc  L01DB07mitoxantrone
http://www.whocc.no/atc  L01DB08pirarubicin
http://www.whocc.no/atc  L01DB09valrubicin
http://www.whocc.no/atc  L01DB10amrubicin
http://www.whocc.no/atc  L01DB11pixantrone
http://www.whocc.no/atc  L01DC01bleomycin
http://www.whocc.no/atc  L01DC02plicamycin
http://www.whocc.no/atc  L01DC03mitomycin
http://www.whocc.no/atc  L01DC04ixabepilone
http://www.whocc.no/atc  L01XA01cisplatin
http://www.whocc.no/atc  L01XA02carboplatin
http://www.whocc.no/atc  L01XA03oxaliplatin
http://www.whocc.no/atc  L01XA04satraplatin
http://www.whocc.no/atc  L01XA05polyplatillen
http://www.whocc.no/atc  L01XB01procarbazine
http://www.whocc.no/atc  L01FX01edrecolomab
http://www.whocc.no/atc  L01FA01rituximab
http://www.whocc.no/atc  L01FD01trastuzumab
http://www.whocc.no/atc  L04AG06alemtuzumab
http://www.whocc.no/atc  L01FX02gemtuzumab ozogamicin
http://www.whocc.no/atc  L01FE01cetuximab
http://www.whocc.no/atc  L01FG01bevacizumab
http://www.whocc.no/atc  L01FE02panitumumab
http://www.whocc.no/atc  L01FX03catumaxomab
http://www.whocc.no/atc  L01FA02ofatumumab
http://www.whocc.no/atc  L01FX04ipilimumab
http://www.whocc.no/atc  L01FX05brentuximab vedotin
http://www.whocc.no/atc  L01FD02pertuzumab
http://www.whocc.no/atc  L01FD03trastuzumab emtansine
http://www.whocc.no/atc  L01FA03obinutuzumab
http://www.whocc.no/atc  L01FX06dinutuximab beta
http://www.whocc.no/atc  L01FF01nivolumab
http://www.whocc.no/atc  L01FF02pembrolizumab
http://www.whocc.no/atc  L01FX07blinatumomab
http://www.whocc.no/atc  L01FG02ramucirumab
http://www.whocc.no/atc  L01FE03necitumumab
http://www.whocc.no/atc  L01FX08elotuzumab
http://www.whocc.no/atc  L01FC01daratumumab
http://www.whocc.no/atc  L01FX09mogamulizumab
http://www.whocc.no/atc  L01FB01inotuzumab ozogamicin
http://www.whocc.no/atc  L01FX10olaratumab
http://www.whocc.no/atc  L01XD01porfimer sodium
http://www.whocc.no/atc  L01XD03methyl aminolevulinate
http://www.whocc.no/atc  L01XD04aminolevulinic acid
http://www.whocc.no/atc  L01XD05temoporfin
http://www.whocc.no/atc  L01XD06efaproxiral
http://www.whocc.no/atc  L01EA01imatinib
http://www.whocc.no/atc  L01EB01gefitinib
http://www.whocc.no/atc  L01EB02erlotinib
http://www.whocc.no/atc  L01EX01sunitinib
http://www.whocc.no/atc  L01EX02sorafenib
http://www.whocc.no/atc  L01EA02dasatinib
http://www.whocc.no/atc  L01EH01lapatinib
http://www.whocc.no/atc  L01EA03nilotinib
http://www.whocc.no/atc  L01EG01temsirolimus
http://www.whocc.no/atc  L01EG02everolimus
http://www.whocc.no/atc  L01EX03pazopanib
http://www.whocc.no/atc  L01EX04vandetanib
http://www.whocc.no/atc  L01EB03afatinib
http://www.whocc.no/atc  L01EA04bosutinib
http://www.whocc.no/atc  L01EC01vemurafenib
http://www.whocc.no/atc  L01ED01crizotinib
http://www.whocc.no/atc  L01EK01axitinib
http://www.whocc.no/atc  D11AH09ruxolitinib
http://www.whocc.no/atc  L01EG03ridaforolimus
http://www.whocc.no/atc  L01EX05regorafenib
http://www.whocc.no/atc  L01EX06masitinib
http://www.whocc.no/atc  L01EC02dabrafenib
http://www.whocc.no/atc  L01EA05ponatinib
http://www.whocc.no/atc  L01EE01trametinib
http://www.whocc.no/atc  L01EX07cabozantinib
http://www.whocc.no/atc  L01EL01ibrutinib
http://www.whocc.no/atc  L01ED02ceritinib
http://www.whocc.no/atc  L01EX08lenvatinib
http://www.whocc.no/atc  L01EX09nintedanib
http://www.whocc.no/atc  L01EK02cediranib
http://www.whocc.no/atc  L01EF01palbociclib
http://www.whocc.no/atc  L01EK03tivozanib
http://www.whocc.no/atc  L01EB04osimertinib
http://www.whocc.no/atc  L01ED03alectinib
http://www.whocc.no/atc  L01EB05rociletinib
http://www.whocc.no/atc  L01EE02cobimetinib
http://www.whocc.no/atc  L01EX10midostaurin
http://www.whocc.no/atc  L01EB06olmutinib
http://www.whocc.no/atc  L01XXOther antineoplastic agents
http://www.whocc.no/atc  L01XX01amsacrine
http://www.whocc.no/atc  L01XX02asparaginase
http://www.whocc.no/atc  L01XX03altretamine
http://www.whocc.no/atc  L01XX05hydroxycarbamide
http://www.whocc.no/atc  L01XX07lonidamine
http://www.whocc.no/atc  L01XX08pentostatin
http://www.whocc.no/atc  P01CX04miltefosine
http://www.whocc.no/atc  L01XX10masoprocol
http://www.whocc.no/atc  L01XX11estramustine
http://www.whocc.no/atc  D10AD01tretinoin
http://www.whocc.no/atc  L01XX16mitoguazone
http://www.whocc.no/atc  L01CE01topotecan
http://www.whocc.no/atc  L01XX18tiazofurine
http://www.whocc.no/atc  L01CE02irinotecan
http://www.whocc.no/atc  D11AH04alitretinoin
http://www.whocc.no/atc  L01XX23mitotane
http://www.whocc.no/atc  L01XX24pegaspargase
http://www.whocc.no/atc  L01XF03bexarotene
http://www.whocc.no/atc  L01XX27arsenic trioxide
http://www.whocc.no/atc  L01XX29denileukin diftitox
http://www.whocc.no/atc  L01XG01bortezomib
http://www.whocc.no/atc  L01XX33celecoxib
http://www.whocc.no/atc  L01XX35anagrelide
http://www.whocc.no/atc  L01XX36oblimersen
http://www.whocc.no/atc  L01XL01sitimagene ceradenovec
http://www.whocc.no/atc  L01XH01vorinostat
http://www.whocc.no/atc  L01XH02romidepsin
http://www.whocc.no/atc  L01XX40omacetaxine mepesuccinate
http://www.whocc.no/atc  L01XX41eribulin
http://www.whocc.no/atc  L01XH03panobinostat
http://www.whocc.no/atc  L01XJ01vismodegib
http://www.whocc.no/atc  L01XX44aflibercept
http://www.whocc.no/atc  L01XG02carfilzomib
http://www.whocc.no/atc  L01XK01olaparib
http://www.whocc.no/atc  L01EM01idelalisib
http://www.whocc.no/atc  L01XJ02sonidegib
http://www.whocc.no/atc  L01XH04belinostat
http://www.whocc.no/atc  L01XG03ixazomib
http://www.whocc.no/atc  L01XL02talimogene laherparepvec
http://www.whocc.no/atc  L01XX52venetoclax
http://www.whocc.no/atc  L01XX53vosaroxin
http://www.whocc.no/atc  L01XYCombinations of antineoplastic agents
http://www.whocc.no/atc  G03CB02diethylstilbestrol
http://www.whocc.no/atc  L02AA02polyestradiol phosphate
http://www.whocc.no/atc  G03CA01ethinylestradiol
http://www.whocc.no/atc  L02AA04fosfestrol
http://www.whocc.no/atc  G03AC05megestrol
http://www.whocc.no/atc  G03AC06medroxyprogesterone
http://www.whocc.no/atc  G03DA01gestonorone
http://www.whocc.no/atc  L02AE01buserelin
http://www.whocc.no/atc  L02AE02leuprorelin
http://www.whocc.no/atc  L02AE03goserelin
http://www.whocc.no/atc  L02AE04triptorelin
http://www.whocc.no/atc  L02AE05histrelin
http://www.whocc.no/atc  L02BA01tamoxifen
http://www.whocc.no/atc  L02BA02toremifene
http://www.whocc.no/atc  L02BA03fulvestrant
http://www.whocc.no/atc  L02BB01flutamide
http://www.whocc.no/atc  L02BB02nilutamide
http://www.whocc.no/atc  L02BB03bicalutamide
http://www.whocc.no/atc  L02BB04enzalutamide
http://www.whocc.no/atc  L02BG01aminoglutethimide
http://www.whocc.no/atc  L02BG02formestane
http://www.whocc.no/atc  L02BG03anastrozole
http://www.whocc.no/atc  L02BG04letrozole
http://www.whocc.no/atc  L02BG05vorozole
http://www.whocc.no/atc  L02BG06exemestane
http://www.whocc.no/atc  L02BX01abarelix
http://www.whocc.no/atc  L02BX02degarelix
http://www.whocc.no/atc  L02BX03abiraterone
http://www.whocc.no/atc  L03AA02filgrastim
http://www.whocc.no/atc  L03AA03molgramostim
http://www.whocc.no/atc  L03AA09sargramostim
http://www.whocc.no/atc  L03AA10lenograstim
http://www.whocc.no/atc  L03AA12ancestim
http://www.whocc.no/atc  L03AA13pegfilgrastim
http://www.whocc.no/atc  L03AA14lipegfilgrastim
http://www.whocc.no/atc  L03AA15balugrastim
http://www.whocc.no/atc  L03AA16empegfilgrastim
http://www.whocc.no/atc  L03AB01interferon alfa natural
http://www.whocc.no/atc  L03AB02interferon beta natural
http://www.whocc.no/atc  L03AB03interferon gamma
http://www.whocc.no/atc  L03AB04interferon alfa-2a
http://www.whocc.no/atc  L03AB05interferon alfa-2b
http://www.whocc.no/atc  L03AB06interferon alfa-n1
http://www.whocc.no/atc  L03AB07interferon beta-1a
http://www.whocc.no/atc  L03AB08interferon beta-1b
http://www.whocc.no/atc  L03AB09interferon alfacon-1
http://www.whocc.no/atc  L03AB10peginterferon alfa-2b
http://www.whocc.no/atc  L03AB11peginterferon alfa-2a
http://www.whocc.no/atc  L03AB12albinterferon alfa-2b
http://www.whocc.no/atc  L03AB13peginterferon beta-1a
http://www.whocc.no/atc  L03AB14cepeginterferon alfa-2b
http://www.whocc.no/atc  L03AB60peginterferon alfa-2b, combinations
http://www.whocc.no/atc  L03AB61peginterferon alfa-2a, combinations
http://www.whocc.no/atc  L03AC01aldesleukin
http://www.whocc.no/atc  L03AC02oprelvekin
http://www.whocc.no/atc  L03AX01lentinan
http://www.whocc.no/atc  L03AX02roquinimex
http://www.whocc.no/atc  L03AX03BCG vaccine
http://www.whocc.no/atc  L03AX04pegademase
http://www.whocc.no/atc  L03AX05pidotimod
http://www.whocc.no/atc  L03AX07poly I:C
http://www.whocc.no/atc  L03AX08poly ICLC
http://www.whocc.no/atc  L03AX09thymopentin
http://www.whocc.no/atc  L03AX10immunocyanin
http://www.whocc.no/atc  L03AX11tasonermin
http://www.whocc.no/atc  L03AX12melanoma vaccine
http://www.whocc.no/atc  L03AX13glatiramer acetate
http://www.whocc.no/atc  L03AX14histamine dihydrochloride
http://www.whocc.no/atc  L03AX15mifamurtide
http://www.whocc.no/atc  L03AX16plerixafor
http://www.whocc.no/atc  L03AX17sipuleucel-T
http://www.whocc.no/atc  L03AX18cridanimod
http://www.whocc.no/atc  L03AX19dasiprotimut-T
http://www.whocc.no/atc  L04AG01muromonab-CD3
http://www.whocc.no/atc  L04AA03antilymphocyte immunoglobulin (horse)
http://www.whocc.no/atc  L04AA04antithymocyte immunoglobulin (rabbit)
http://www.whocc.no/atc  L04AA06mycophenolic acid
http://www.whocc.no/atc  L01EG04sirolimus
http://www.whocc.no/atc  L04AK01leflunomide
http://www.whocc.no/atc  L04AA15alefacept
http://www.whocc.no/atc  L04AA19gusperimus
http://www.whocc.no/atc  L04AG02efalizumab
http://www.whocc.no/atc  L04AA22abetimus
http://www.whocc.no/atc  L04AG03natalizumab
http://www.whocc.no/atc  L04AA24abatacept
http://www.whocc.no/atc  L04AJ01eculizumab
http://www.whocc.no/atc  L04AG04belimumab
http://www.whocc.no/atc  L04AE01fingolimod
http://www.whocc.no/atc  L04AA28belatacept
http://www.whocc.no/atc  L04AF01tofacitinib
http://www.whocc.no/atc  L04AK02teriflunomide
http://www.whocc.no/atc  L04AA32apremilast
http://www.whocc.no/atc  L04AG05vedolizumab
http://www.whocc.no/atc  L04AG07begelomab
http://www.whocc.no/atc  L04AG08ocrelizumab
http://www.whocc.no/atc  L04AF02baricitinib
http://www.whocc.no/atc  L04AB01etanercept
http://www.whocc.no/atc  L04AB02infliximab
http://www.whocc.no/atc  L04AB03afelimomab
http://www.whocc.no/atc  L04AB04adalimumab
http://www.whocc.no/atc  L04AB05certolizumab pegol
http://www.whocc.no/atc  L04AB06golimumab
http://www.whocc.no/atc  L04AC01daclizumab
http://www.whocc.no/atc  L04AC02basiliximab
http://www.whocc.no/atc  L04AC03anakinra
http://www.whocc.no/atc  L04AC04rilonacept
http://www.whocc.no/atc  L04AC05ustekinumab
http://www.whocc.no/atc  R03DX09mepolizumab
http://www.whocc.no/atc  L04AC07tocilizumab
http://www.whocc.no/atc  L04AC08canakinumab
http://www.whocc.no/atc  L04AC09briakinumab
http://www.whocc.no/atc  L04AC10secukinumab
http://www.whocc.no/atc  L04AC11siltuximab
http://www.whocc.no/atc  L04AC12brodalumab
http://www.whocc.no/atc  L04AC13ixekizumab
http://www.whocc.no/atc  L04AC14sarilumab
http://www.whocc.no/atc  L04AD01ciclosporin
http://www.whocc.no/atc  D11AH01tacrolimus
http://www.whocc.no/atc  L04AD03voclosporin
http://www.whocc.no/atc  L04AX01azathioprine
http://www.whocc.no/atc  L04AX02thalidomide
http://www.whocc.no/atc  L04AX04lenalidomide
http://www.whocc.no/atc  L04AX05pirfenidone
http://www.whocc.no/atc  L04AX06pomalidomide

Explanation of the columns that may appear on this page:

Level A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
System The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code The code (used as the code in the resource instance)
Display The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition An explanation of the meaning of the concept
Comments Additional notes about how to use the code